Secondary hyperparathyroidism (SHPT), characterized by severely elevated parathyroid hormone levels (PTH), is a common metabolic abnormality and a potentially modifiable dementia risk factor in ESRD patients. This evidence concerns the gene PTH and secondary hyperparathyroidism.